Hester Biosciences Limited has informed the Exchange that Board of Directors at its meeting held on May 15, 2026, recommended Final Dividend of Rs. 11 per equity share.
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences reported strong FY26 results with standalone profit after tax jumping 63.6% to Rs. 521 million (vs Rs. 318.4 million in FY25) and consolidated PAT nearly doubling to Rs. 574.8 million. Standalone revenue grew marginally to Rs. 2,921 million while consolidated revenue rose to Rs. 3,326 million. The Board recommended a final dividend of Rs. 11 per equity share (110% on Rs. 10 face value) for FY26, subject to shareholder approval at the AGM. The company also completed divestment of its 43.81% stake in Texas Lifescience Private Limited in March 2026. Unmodified audit opinions were issued by statutory auditors for both standalone and consolidated financials.
The dividend recommendation signals management confidence in sustained profitability growth. Shareholders can expect positive sentiment given the near-doubling of consolidated earnings and healthy cash generation of Rs. 509 million from standalone operations.